Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO

INDIANAPOLIS, May 16, 2011 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
will present data from more than 30 studies at the 47th Annual Meeting of the
American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 – 7,
2011, including results from PARAMOUNT, a Phase III study of an ALIMTA-based
continuation maintenance regimen for the treatment of advanced nonsquamous
non-small cell lung cancer. PARAMOUNT data will be included in the
ASCO-sponsored press briefing the morning of June 5 followed by a presentation
during the Lung Cancer Oral Abstract Session at ASCO later the same day.

At ASCO, Lilly will present the latest research results on ALIMTA® (pemetrexed
for injection) and GEMZAR® (gemcitabine for injection), as well as ERBITUX®
(cetuximab) with partners Bristol-Myers Squibb and Merck KGaA.

“Lilly Oncology is committed to exploring innovations that improve outcomes for
all people living with cancer,” said Richard Gaynor, M.D., vice president,
product development and medical affairs for Lilly Oncology. “We believe that
data from PARAMOUNT, and our other studies at ASCO, demonstrate Lilly’s focus on
tailored therapies, and commitment to addressing unmet needs in cancer care.”

ALIMTA Oral Abstract Session:

— Abstract # CRA7510: Sunday, June 5, 2011, 11:30 – 11:45 AM
o PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best
supportive care (BSC) versus placebo plus BSC immediately following
induction treatment with pem plus cisplatin for advanced nonsquamous
non-small cell lung cancer (NSCLC)
o Author/Speaker: L. G. Paz-Ares, F. de Marinis, M. Dedui, M. Thomas,
J.P. Pujol, P. Bidoli, O. Molinier, T.P. Sahoo, E. Laack, M. Reck, J.
Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C.
Visseren-Grul, C. Gridelli
o Location: Hall D1

P-LLY

This press release contains forward-looking statements about the potential
ofALIMTAand reflects Lilly’s current beliefs. However, as with any
pharmaceutical product, there are substantial risks and uncertainties in the
process of development and commercialization. There is no guarantee that the
product willcontinue to becommercially successful. For further discussion of
these and other risks and uncertainties, see Lilly’s filings with the United
States Securities and Exchange Commission. Lilly undertakes no duty to update
forward-looking statements.

SOURCE Eli Lilly and Company